P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer (Q36538788)

14 August 2017

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mari Mino-Kenudson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Takuya Sakashita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Noriko Yanagitani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Hironori Ninomiya

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Atsushi Horiike

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Justin F Gainor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Akito Dobashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Seiji Sakata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yuichi Tambo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Satoru Kitazono

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Shigeo Sato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Sumie Koike

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A John Iafrate

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yuichi Ishikawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Alice T Shaw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jeffrey A Engelman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Makoto Nishio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

12 December 2015

1 reference

14 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

54-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

12 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Ceritinib in ALK-rearranged non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

ALK in lung cancer: past, present, and future

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Characterization of a side population of cancer cells from human gastrointestinal system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Multidrug resistance in cancer: role of ATP-dependent transporters

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

ABC transporters in cancer: more than just drug efflux pumps.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

Reversal of multidrug resistance by a novel quinoline derivative, MS-209.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4739423

A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib

21 September 2018

1 reference

12 December 2020

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil

1 reference

12 December 2020

Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines

1 reference

12 December 2020

Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer

1 reference

12 December 2020

10.1016/J.EBIOM.2015.12.009

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PubMed publication ID

26870817

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26870817%20AND%20SRC:MED&resulttype=core&format=json